Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season-Reference-Cited by-同舟云学术

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season

Published:2024-03-06 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Machado Marina Amaral de Avila¹,Gandhi-Banga Sonja¹,Gallo Sophie²,Cousseau Tathyana Giannotti³,Byrareddy Reddappa Maniganahally⁴,Nissilä Markku⁵,Schelling Jörg⁶,Monfredo Celine⁷

Affiliation:

1. Epidemiology & Benefit-Risk, Sanofi, Toronto, Canada

2. Medical Operations, Sanofi, Lyon, France

3. Patient Safety and Pharmacovigilance, Sanofi, Sao Paulo, Brazil

4. Patient Safety and Pharmacovigilance, Sanofi, Bangalore, India

5. Terveystalo Biobank and Clinical Research, Turku, Finland

6. Department of Medicine IV, LMU University Hospital, Munich, Germany

7. Biostatistical Sciences, Sanofi, Marcy l’Etoile, France

Funder

Sanofi

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2322196

Reference22 articles.

1. Pharmacovigilance risk assessment committee (PRAC) EMA. Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU; 2014 [accessed 2014 Apr 10]. https://www.ema.europa.eu/en/interim-guidance-enhanced-safety-surveillance-seasonal-influenza-vaccines-eu-scientific-guideline.

2. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety

3. Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16

4. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season

5. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria;Clothier HJ;Commun Dis Intell Q Rep,2011